

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Madaline Chirica, *et al.*

Application No.: 10/720,026

Filed: November 21, 2003

For: MAMMALIAN RECEPTOR PROTEIN
DCRS5; METHODS OF TREATMENT
(as amended)

Examiner: J. Seharaseyon

Art Unit: 1647

Conf. No.: 3154

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

(a) Pursuant to the duty of disclosure under 37 C.F.R. § 1.56, it is requested that the documents listed on the accompanying Form PTO/SB/08 be considered and made of record in the above-identified patent application. Copy(ies) of these documents ☒ are enclosed ☐ were filed in related U.S. Application No(s) _____ filed _____, respectively.

Pursuant to the USPTO waiver of the requirement under 37 CFR 1.98 (a)(2)(I), copies of cited U.S. patents and patent application publications are not attached.

(b) No fee is believed due because:

- ☐ This Information Disclosure Statement is being submitted concurrently with the filing of the above-identified application; **or**
- ☐ This Information Disclosure Statement is being submitted concurrently with a Request for Continued Examination (RCE); **or**
- ☐ This Information Disclosure Statement is being submitted prior to the mailing of a first Office Action on the merits.

(c) ☒ This Information Disclosure Statement is being submitted before the mailing date of any final action, notice of allowance, or an action that otherwise closes prosecution; and:

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three

months prior to the filing of this Information Disclosure Statement;
or

☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c), more than three months prior to the filing of this Information Disclosure Statement; **or**

☒ The Commissioner is hereby authorized to charge the requisite fee.

(d) ☐ This Information Disclosure Statement is being submitted on or before the payment of the issue fee; and:

☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; **or**

☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c), more than three months prior to the filing of this Information Disclosure Statement; **and**

☐ The Commissioner is hereby authorized to charge the requisite fee.

☒ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 04-1239.

Respectfully submitted,

Date: 8 November 2007

By: /Gregory R. Bellomy/
Gregory R. Bellomy, Reg. No. 48,451
Attorney for Applicants

Customer No. 028008
DNAX Research, Inc.
901 California Avenue
Palo Alto, CA 94304-1104
Telephone (Switchboard): (650) 496-6400
Telephone No. (Direct): (650) 496-6565
Facsimile No.: (650) 496-1200